Analysis of the DepMap dataset9–11 revealed that NAMPT-KO effects in SCLC were more robust than in pan-cancer or NSCLC groups (Fig. 2d) but similar to the AML group (Supplementary Fig. 1h). This evidence concerns the gene NAMPT and acute myeloid leukemia.